Usual causative organisms | Initial parenteral antimicrobial regimens | Empiric oral step-down regimens |
Community-acquired infection in immunocompetent patients | ||
Staphylococcus aureus, viridans streptococci and other streptococci, Haemophilus influenzae, oral anaerobes (Peptostreptococci, Fusobacterium, etc) |
If therapy against MRSA is indicated¶, add one of the following to the above regimens:
|
If therapy against MRSA is indicated◊, add one of the following to the above regimens:
|
Hospital-acquired infection or immunocompromised patients | ||
Staphylococcus aureus (including MRSA), viridans streptococci and other streptococci, Haemophilus influenzae, Pseudomonas aeruginosa, Enterobacterales, oral anaerobes (eg, Peptostreptococci, Fusobacterium) |
Plus one of the following regimens:
|
If therapy against MRSA is indicated◊ and clindamycin cannot be used§:
|
ESBL: extended-spectrum-beta-lactamase; IV: intravenous; MRSA: methicillin-resistant Staphylococcus aureus.
* Fluoroquinolones should be reserved for patients who cannot tolerate or have contraindications to the beta-lactam regimens.
¶ Risk factors for MRSA infection include history of IV drug use, recent antibiotic use, recent surgery, residence in a long-term care facility, discharge from a hospital within the preceding 12 months, or hemodialysis. Immunocompromised patients or patients with a hospital-acquired infection are also at risk for MRSA.
Δ For severely ill patients, a vancomycin loading dose (20 to 35 mg/kg) is appropriate; within this range, we use a higher dose for critically ill patients. The loading dose is based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg. The initial maintenance dose and interval are determined by nomogram (typically 15 to 20 mg/kg every 8 to 12 hours for most patients with normal renal function). Subsequent dose and interval adjustments are based on area under the curve-guided or trough-guided serum concentration monitoring. Refer to the UpToDate topic on vancomycin dosing for sample nomogram and discussion of vancomycin monitoring.
◊ MRSA therapy is indicated if MRSA was isolated on culture or as part of the initial empiric regimen in circumstances where no culture data is available and risk factors for MRSA are present. (Refer to ¶ footnote for list of MRSA risk factors).
§ MRSA susceptibility to clindamycin should be documented if this regimen is used for anti-MRSA therapy.